A new strategy for faster urinary biomarkers identification by Nano-LC-MALDI-TOF/TOF mass spectrometry by Benkali, K et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Genomics
Open Access Methodology article
A new strategy for faster urinary biomarkers identification by 
Nano-LC-MALDI-TOF/TOF mass spectrometry
K Benkali1, P Marquet1, JP Rérolle2, Y Le Meur1,3 and LN Gastinel*1
Address: 1INSERM U850, France; Univ. of Limoges, France; CHU Limoges, France, 2Department of Nephrologie-Transplantation, University 
Hospital, Limoges, France and 3Department of Nephrologie-Transplantation, University Hospital, Brest, France
Email: K Benkali - khaled.benkali@etu.unilim.fr; P Marquet - pierre.marquet@unilim.fr; JP Rérolle - jean-philippe.rerolle@chu-limoges.fr; Y Le 
Meur - yannick.lemeur@chu-brest.fr; LN Gastinel* - louis.gastinel@unilim.fr
* Corresponding author    
Abstract
Background:  LC-MALDI-TOF/TOF analysis is a potent tool in biomarkers discovery
characterized by its high sensitivity and high throughput capacity. However, methods based on
MALDI-TOF/TOF for biomarkers discovery still need optimization, in particular to reduce analysis
time and to evaluate their reproducibility for peak intensities measurement. The aims of this
methodological study were: (i) to optimize and critically evaluate each step of urine biomarker
discovery method based on Nano-LC coupled off-line to MALDI-TOF/TOF, taking full advantage
of the dual decoupling between Nano-LC, MS and MS/MS to reduce the overall analysis time; (ii)
to evaluate the quantitative performance and reproducibility of nano-LC-MALDI analysis in
biomarker discovery; and (iii) to evaluate the robustness of biomarkers selection.
Results: A pool of urine sample spiked at increasing concentrations with a mixture of standard
peptides was used as a specimen for biological samples with or without biomarkers. Extraction and
nano-LC-MS variabilities were estimated by analyzing in triplicates and hexaplicates, respectively.
The stability of chromatographic fractions immobilised with MALDI matrix on MALDI plates was
evaluated by successive MS acquisitions after different storage times at different temperatures.
Low coefficient of variation (CV%: 10–22%) and high correlation (R2 > 0.96) values were obtained
for the quantification of the spiked peptides, allowing quantification of these peptides in the low
fentomole range, correct group discrimination and selection of "specific" markers using principal
component analysis. Excellent peptide integrity and stable signal intensity were found when MALDI
plates were stored for periods of up to 2 months at +4°C. This allowed storage of MALDI plates
between LC separation and MS acquisition (first decoupling), and between MS and MSMS
acquisitions while the selection of inter-group discriminative ions is done (second decoupling).
Finally the recording of MSMS spectra to obtain structural information was focused only on
discriminative ions in order to minimize analysis time.
Conclusion:  Contrary to other classical approaches with direct online coupling of
chromatographic separation and on the flight MS and/or MSMS data acquisition for all detected
analytes, our dual decoupling strategy allowed us to focus on the most discriminative analytes,
giving us more time to acquire more replicates of the same urine samples thus increasing detection
sensitivity and mass precision.
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Background
Non invasive monitoring of the kidney status using urine
biomarkers can lead to the early diagnosis of renal dys-
function, which might help avoid or diminish the use of
invasive methods like renal biopsy and improve patients
treatment and survival particularly in renal or uro-genital
pathologies such as renal cancers, diabetic nephropathy
or allograft dysfunctions in renal transplantation.
Several urine biomarker discovery studies in renal diseases
have been published, most of which used Surface
Enhanced Laser Desorption Ionization-Time of Flight
Mass spectrometry (SELDI-TOF MS) which is character-
ized by its poor resolution but high throughput capacity
[1-3]. Recently, Capillary Electrophoresis-Mass Spectrom-
etry (CE-MS) has been largely used in urinary peptidomic
studies for biomarkers discovery, giving rise to many pub-
lished results though sometimes without protein or pep-
tide identification [4-6]. Also, different candidate
biomarkers have thus been proposed for the same pathol-
ogy, none of which have been validated in a large popula-
tion. Such diversity may be due to the inter- and intra-
individual variability in the urine proteome, and/or to dif-
ferences in urine sampling, storage and analysis proce-
dures across different studies [7]. Some authors gave
recommendations for the standardization of proteomic
analysis procedures, particularly for the pre-analytical
phase (sample collection, storage, and preparation). Pre-
ventive measures must be taken to avoid alterations of the
urinary proteome and peptidome composition due to
bacterial growth [8], storage conditions, freeze-thaw
cycles, pH conditions, etc [8-11].
LC-MALDI-TOF/TOF analysis is a new potential tool for
biomarkers discovery because of its high sensitivity and
high throughput capacity [12]. However, the use of
MALDI-TOF/TOF as an analytical tool in clinical research
still needs optimization and evaluation [13]. One of the
major limitations of the MALDI-based technique is its rel-
ative poor reproducibility in measuring m/z abundances
(peak intensity), which may be essential in biomarker dis-
covery where all-or-nothing variations are probably not
the most frequent [14]. In addition, LC-MALDI-TOF/TOF
analysis generally takes a long time, which is hardly prac-
tical when analysing large numbers of samples. However,
this technique is recognized for its high mass precision
(typically in the range of 5 ppm to 20 ppm routinely).
The aims of the present study were: (i) to optimize and
critically evaluate each step of a comprehensive urine
biomarker discovery method based on Nano-LC coupled
off-line to MALDI-TOF/TOF, taking full advantage of the
dual decoupling between Nano-LC, MS and MS/MS to
reduce the overall analysis time and increase the tech-
nique throughput, as will be requested during the valida-
tion phase involving a larger population set; (ii) to
evaluate the quantitative performance and reproducibility
of nano-LC-MALDI analysis in biomarker discovery; and
(iii) to evaluate the robustness of biomarkers selection
using pseudo-biomarker peptides.
Methods
Sample collection
Urine samples from 3 healthy volunteers who had not
recently received any medication were used. All subjects
gave their written informed consent to participate in this
study. A sample of 40 ml of mid-stream urine was col-
lected in a polypropylene tube containing one COM-
PLETE™ Mini tablet (Roche Diagnostics, Mannheim,
Germany) to inactivate endogenous and exogenous pro-
teases, and sodium azide at a final concentration of 2 mg/
ml to prevent bacterial growth. Cells or other insoluble
materials (debris, crystals and aggregated materials) were
cleared from the samples by centrifugation at low speed
(2500 rpm, 1 h at 4°C), then 5 ml urine sample aliquots
were transferred in polypropylene tubes, lyophilized, and
stored at -80°C until their usage.
Urine sample processing
Before nanoLC-MALDI MS analysis, each stored sample of
lyophilized urine was reconstituted with 2 ml of 0.1% tri-
fluoro-acetic acid (TFA) (Sigma-Aldrich, St Louis, MO,
USA) in HPLC grade water and submitted to solid phase
extraction (SPE) on a C2 ethyl 2.5 mL cartridge (Amer-
sham Biosciences, Buckinghamshire, England), following
the standard procedure recommended by the vendor. Uri-
nary peptides were eluted with acetonitrile/water (50/50,
v/v) solution containing 0.5% formic acid. The eluate was
finally evaporated using a SpeedVac® system (Thermo-
Fisher, Château Gontier, France) and then resuspended in
70 μL of 0.1% TFA. Peptides and proteins concentrations
were measured using Bradford reagent (Sigma-Aldrich, St
Louis, MO, USA). Then, 70 μl of the urine extract were
mixed with 2 μl of the Proteomix 4 peptides calibrator
(Laserbio, Sophia-Antipolis, France) consisting of:
Human angiotensin II (1046.54 Da, at 21 pmol/μl); neu-
rotensin (1672.91 Da, at 14 pmol/μl); ACTH 18–39 frag-
ment (2465.19 Da, at 17.5 pmol/μl); and insulin β chain
oxidized (3494.65 Da, at 87.5 pmol/μl). Peptide calibra-
tors were used for subsequent time-shift alignment and
intensity normalization of the Nano-LC-MALDI MS
reconstituted chromatograms.
Urinary peptides separation using Nano-HPLC
Chromatographic separation of peptides was performed
using an Ultimate 3000 nano-HPLC system (LC Packings,
DIONEX, Sunnyvale, USA) equipped with: a ther-
mostated column compartment, a six-port micro-switch-
ing valve, a dynamic nanoflow splitter with a flow meter,
a micro vacuum degasser and a thermostated microwell-BMC Genomics 2008, 9:541 http://www.biomedcentral.com/1471-2164/9/541
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plate autosampler with a six-port micro-switching valve.
One to five microlitres of reconstituted urine containing
the same relative quantity of materials (2 μg of peptides)
were concentrated on a (0.5 cm × 300 μm i.d.) trapping
column packed with C18 PepMap 100 (LC Packings
DIONEX) using mobile phase A: acetonitrile/water (2:98,
v/v) with 0.1% TFA delivered at 20 μl/min. The trapping
column was switched on-line with the analytical column
after 5 min loading time. Chromatographic separation of
peptides was performed using a C18 PepMap 100 column
(15 cm × 75 μm i.d., LC Packings DIONEX) and using a
linear gradient of B, a mixture of acetonitrile/water
(90:10) with 0.1% TFA, in solvent A, as follows: from 10%
to 45% of B in 150 min, switched to 100% buffer B for 10
min, followed by 10 min re-equilibration with buffer A at
a constant flow rate of 0.3 μl/min, stabilized by an active
splitter (1:1000). The column was directly coupled to a
UV flow cell detector (Ultimate DIONEX) at the exit of
which the effluent was coaxially mixed with a solution of
3.5 mg/ml α-cyano-4-hydroxycinnamic acid MALDI
matrix (α-CHCA) (Sigma-Aldrich, St Louis, MO, USA)
prepared daily and delivered at a flow rate of 0.9 μL/min
(3:1), then directed towards an on-line Probot (LC Pack-
ings DIONEX) plate-spotting system. Each spot repre-
sented a 12-second "fraction" (60 nL) of the reverse phase
gradient. The triplicate runs of each sample, each contain-
ing 600 spots, were distributed on the same MALDI plate.
MALDI-TOF/TOF data acquisition
The spots representing the different chromatographic frac-
tions were analyzed using a 4800 MALDI-TOF/TOF mass
spectrometer (Applied Biosystems/MDS Sciex, Toronto,
Canada), equipped with a neodymium: yttrium-alumi-
num-garnet laser emitting at λ = 355 nm with a repetition
rate of 200 Hz. The mass spectrometer was controlled by
the 4000 Series Explorer, version 3.5.2 program. For MS
analyses, typically 800 spectra were acquired for each spot
in the reflector positive mode in the mass range of 800 to
5000 m/z, with 15 ppm mass tolerance (external calibra-
tion). The spots of fractions eluted before 40 min and after
160 min were not analyzed for the sake of time, as prelim-
inary investigations showed that they apparently con-
tained very little peptide information.
Data processing and analysis
Peak lists obtained from Nano-LC-MALDI-TOF chroma-
tograms were processed using MarkerView version 1.1
(Applied Biosystems/MDS Sciex, Toronto, Canada).
Alignment was first performed with 45% retention time
and 0.5 amu mass tolerances. These settings were opti-
mized values found to give a maximum number of com-
mon peaks between sample replicates. Then, data were
scaled in intensity by normalization to the median inten-
sity of one reference chromatogram (chromatogram with
the highest signal intensity) using MarkerView. After
alignment and normalization, the data were filtered out
from MALDI residual α-CHCA matrix clusters. As most
matrix clusters had masses below 1000 m/z, filtration
consisted in excluding all ions with m/z < 1000.
Principal component analysis (PCA) was performed on
processed data using different scaling options (mean cen-
tre, autoscale, range scale, and Pareto scale [15]) proposed
by MarkerView program. Pareto scaling was finally
retained because of its best grouping performance
explaining the largest variability in three principal compo-
nents vectors (PC > 10%). Pareto data pre-treatment con-
sists of mean centring and scaling by square root of
standard deviation of m/z intensities. The ions were clas-
sified according to the sum of their loading values in the
first three principal components PC1, PC2, and PC3. Ions
with the highest PC loading values were considered as the
most discriminative ions.
MALDI-TOF/TOF MSMS data acquisition
MS/MS data acquisition was only performed on MALDI
plate stored at -20°C, for peptide sequence and protein
identification of these selected discriminative ions. The
typical experiment workflow is summarized in Figure 1.
MS/MS acquisitions were then carried out using air as col-
lision gas at a pressure of ~3.0 × 10-6 torr and collision
energy of 1 kV. Approximately 2,000 spectra were added
up for each spot. The peaks were de-isotoped and only
those with s/n ≥ 10 were retained for interpretation.
Protein identifications using MS and MSMS data
MSMS data were pre-processed by manufacturer compu-
ter program GPS Explorer version 3.6 (Applied Biosys-
tems) and then identification of urine proteins from their
peptides sequences was established using MASCOT search
engine version 2.1 (Matrix Science, Boston, MA) with the
last updated version of Swiss-Prot protein database
merged with random sequences. Methionine oxidation
and Asn and Gln deamidation were selected as the only
variable modifications. The tolerance for precursor ion
and MS/MS fragment mass values was set at 150 ppm and
0.5 Da, respectively. Only the 5 top-ranked peptide
matches were taken into consideration for protein identi-
fication.
Method validation
Extraction recovery
A pool of healthy volunteers' urine was divided in two
aliquots which were spiked with the same amount of a
mixture of four peptides (Human angiotensin II 1046.54
Da 60 pmol/μl; Neurotensin 1672.91 Da, 40 pmol/μl;
ACTH 18–39 fragment 2465.19 Da, 50 pmol/μl; Insulin β
chain oxidized 3494.65 Da, 250 pmol/μl), one aliquot
before and the second after solid phase extraction (SPE)
with the C2-ethyl cartridges. The samples were processedBMC Genomics 2008, 9:541 http://www.biomedcentral.com/1471-2164/9/541
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in triplicate to evaluate the reproducibility of sample
processing and then analyzed in triplicate by nano-LC off-
line MALDI TOF as described above.
Influence of storage conditions on peptides spotted on MALDI plates
The same mixture of four peptides was mixed with α-
CHCA matrix solution at 3.5 mg/ml (1:1, v/v), and 1 μl
was spotted manually 24 times on each of three MALDI
plates. The plates were kept in the dark, one at room tem-
perature, one at +4°C and the third at -20°C, for 2
months. Once a week over this 2 month period, 3 differ-
ent spots per plate were analyzed using MALDI TOF/TOF
in the reflector mode.
Quantitative response and performance of data processing and 
analysis
Quantitative accuracy and reproducibility of MALDI-TOF/
TOF as well as the aptitude of the data pre-processing the
data processing and the data analysis procedures to select
discriminative ions were evaluated by comparing two
samples prepared from C2-extract of a healthy volunteer's
urine aliquot, spiked or not with increasing concentra-
tions of three peptides: Human angiotensin II (1046.54
Da 1X = 120 fmol/μl), neurotensin (1672.91 Da, 1X = 80
fmol/μl) and ACTH 18–39 fragment (2465.19 Da, 1X =
100 fmol/μl). Six replicates of each spiked and non-spiked
aliquots were then analyzed by LC-MALDI-TOF/TOF as
described above, including retention time alignment and
intensity normalization.
Results and discussion
Solid phase extraction and desalting on C2-ethyl car-
tridges resulted in losses of large urinary peptides and
proteins. The synthetic peptides were recovered with
yields of approximately 60%, 80% and 20% for human
angiotensin II (1046.54 Da), neurotensin peptide
Workflow of the dual decoupling procedure based on Nano-LC-MALDI-TOF/TOF for the discovery of urine biomarkers Figure 1
Workflow of the dual decoupling procedure based on Nano-LC-MALDI-TOF/TOF for the discovery of urine 
biomarkers.BMC Genomics 2008, 9:541 http://www.biomedcentral.com/1471-2164/9/541
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(1672.0 Da) and ACTH fragment (2465.19 Da), respec-
tively, while the oxidized bovine insulin beta chain
(3494.5 Da) was totally lost (Figure 2). Some peptides
with m/z > 3000 Da could nevertheless be detected in
urine samples processed this way (approximately 20%
of the detected masses), meaning either that they were
highly concentrated or that peptide loss is not only
related to their size, but also to their structural proper-
ties. A good reproducibility of urine sample processing
was obtained using the SPE C2 ethyl procedure for pep-
tide extraction in spiked urine, showing coefficient of
variation (CV %) of 14%, 20%, and 10% for the human
angiotensin II (1046.54 Da), neurotensin peptide
(1672.0 Da) and ACTH fragment (2465.19 Da), respec-
tively. The non-hydrolyzed urinary peptidome was
studied as a source of potential biomarkers instead of
trypsinized urine proteins and peptides in order to
reduce the complexity of analytes in urines, avoid pro-
tease contaminations and reveal potentially natural or
pathologically induced protease activity in urine of
patients following renal or uro-genital injury [1,16].
Sample desalting and peptide extraction was done on
C2-ethyl cartridges that retain peptides based on their
polarity and size characteristics. Moreover, this step
removes most of intact proteins and consequently
diminishes the large diluting effect caused by major
serum proteins such as human serum albumin, possi-
bly found in urine during physiological episodes of
hypertension or other stresses/exercises, as well as in
different renal diseases [7,17]. This sample preparation
method was also chosen because of possible automa-
tion to increase the analytical throughput. The same
resin was used extensively in formerly published stud-
ies describing urinary peptides as potential biomarkers
[6,5].
A relatively long chromatographic run of 180 min was
chosen in order to obtain the best separation of peptides
without too much loss of sensitivity, resulting in a
decrease of the number of urinary peptides immobilized
per spot/fraction to be analyzed during MS data acquisi-
tion, Aligned and filtered urinary chromatograms con-
tained 657 ions, the spiked peptides were eluted at 48.50
min, 43.17 min and 53.50 min retention time for m/z
1046.54, 1672.94, and 2465.19 respectively (additional
file 1). As only the fractions between 40 and 160 min were
spotted, it resulted in approximately 600 spots per repli-
cate, so that full informative triplicate nanoLC chromato-
grams could be spotted on a single MALDI plate. This
approach decreased plate storage space, cost and mini-
mized plate-to-plate signal variability.
Targeted MSMS analysis (as described in figure 1) allows
sequence peptides identification of spiked pseudo-
biomarkers (additional files 2 to 7).
The MALDI-TOF/TOF MS analysis of one plate typically
took 2.5 hours. While the unsupervised MS/MS analysis
of an entire plate would have taken 16 hours, our actual
targeted MS/MS analysis took 17 seconds per selected ion
and per spot. Complete MS analysis of a urine sample in
triplicate (3 × 600 spots) still took a long time but the
decoupling between MS and MSMS resulted in a gain of
time of approximately 10 fold.
Figure 3 shows that the MS intensity of spotted standard
peptides is roughly stable over time when the plates were
stored at +4°C or -20°C in the dark. At room temperature,
MS intensity of the same peptides decreased by 60% over
a few weeks for all peptides. The excellent structure integ-
rity of peptides immobilized with the MALDI matrix on
the plates stored in the dark at -20°C allowed us to take
advantage of the decoupling between LC, MS, and MS/MS
procedures. First, we performed MS data acquisition only
on all 600 spots in triplicate for each sample, and sec-
ondly MS/MS data acquisition on the most discriminative
ions selected after MS data analysis (20 to 50 ions). This
approach resulted in a dramatic decrease in the MS/MS
data acquisition time. However, the limiting factors of this
process are: the cost of the MALDI plates; the amounts of
immobilized analytes; and our ability to locate precisely
selected analytes by their retention time on immobilized
chromatogram fractions. Moreover, the immobilized
urine samples were sufficiently stable on MALDI plates to
consider sending the plates to different laboratories for
cross-validation on different MALDI-TOF/TOF platforms.
The analysis of 6 replicates of urine aliquots spiked or not
with 3 standard peptides at increasing concentrations
showed that their m/z intensity was linearly correlated
with their concentration (R2 > 0.96) in the range of 10 to
120 fmol/μl (Figure 4). The precision of the measure eval-
uated as mean CV % between the six replicates was 22.4 ±
12.5%, 10 ± 2% and 16.3 ± 7% for m/z 1046.54, 1672.94,
and 2465.19 respectively. Moreover, spiked and non-
spiked urine aliquots were totally discriminated by PCA,
with PC scores of 38.6%, 18% and 10.3% for PC1, PC2,
and PC3, respectively. Figure 5a shows the plot of sample
scores for PC1 and PC2. All six replicates of spiked urine
are clustered, as well as 5 out of 6 of the non-spiked urine
replicates. Furthermore, the plot of the loading values for
PC1 and PC2 (Figure 5b) shows that the most discrimina-
tive ions with the highest positive loadings on PC1 and
PC2 are the spiked peptides. The spiked peptides were the
top ranked discriminative peptides according to their PC
loadings at the highest concentration (120–100 fento-
mole/μl) but not at their lowest (20–30 fentomole/μl),
although they were still among the top ten of the most dis-
criminative ions. The loadings of spiked peptides accord-
ing to their concentration are summarized in Table 1. In
addition, PCA classified correctly spiked and non-spikedBMC Genomics 2008, 9:541 http://www.biomedcentral.com/1471-2164/9/541
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urine aliquots at each spiked peptide concentration (data
Recovery of spiked peptides after C2-ethyl solid phase extraction of a healthy volunteer's urine sample Figure 2
Recovery of spiked peptides after C2-ethyl solid phase extraction of a healthy volunteer's urine sample. Signal 
intensities of 4 standard peptides were evaluated before and after C2 ethyl SPE extraction. Error bars represented SD of trip-
licate measurements.
Specific peptides MS signal intensity versus time after plate storage at 3 different temperatures (25°C, 4°C, -20°C) Figure 3
Specific peptides MS signal intensity versus time after plate storage at 3 different temperatures (25°C, 4°C, -
20°C). (a) human angiotensin II (MW = 1046.54), (b) neurotensin (MW = 1672.91), (c) ACTH fragment 18–39 (MW = 
2465.19), and (d) oxidized insulin B chain (MW = 3494.65). Error bars represented SD from triplicate measurements.BMC Genomics 2008, 9:541 http://www.biomedcentral.com/1471-2164/9/541
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not shown). Good correlation was found between spiked
peptide concentrations and m/z intensity, even though it
is known that MALDI ionization yields poor reproducibil-
ity of peak intensity, particularly due to poor inter-spot
crystallization reproducibility [14]. Quantification preci-
sion (CV%: 10–22%) was sufficient here to allow semi-
quantitative estimation in the low fentomole range. The
use of an internal peptide calibration using Glu1-Fibri-
nopeptide B diluted in the matrix for precision purposes
and correction of matrix crystallization variability was
investigated, but not pursued because of its important ion
suppression effect on the other analytes, particularly at
low concentrations (data not shown). However, our MS
data acquisition strategy consisted in recording MS spectra
resulting from 800 laser shots (accumulation of 50 MS
spectra at each of 16 random locations on a spot, i.e. 16
sub-spectra), thus improving signal-to-noise ratio and
sensitivity, as well as quantification precision.
Conclusion
This study showed the beneficial effect of a dual decou-
pling strategy between Nano-LC MALDI-TOF and TOF/
TOF mass spectrometry on overall analytical time. Associ-
ated with PCA, this method allowed successful discrimi-
nation of urine samples spiked or not with low
fentomole/μl synthetic peptides used as pseudo-biomark-
ers. This method is currently being applied to the discov-
ery phase of potential urine biomarkers of graft rejection
in kidney transplant patients.
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Quantitative performance of MALDI-TOF/TOF for 
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otensin II (1046.54 Da, higest concentration 1X = 120 fmol/
μl), neurotensin (1672.91 Da, 1X = 80 fmol/μl) and ACTH 
18–39 fragment (2465.19 Da, 1X = 100 fmol/μl). Each sample 
was analyzed six times.
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Observed MSMS spectrum of pseudo-biomarker with m/z 1046.54.
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Mascot interpretation of MSMS fragmentation spectrum of pseudo-
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Click here for file
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Additional file 4
MSMS spectra and fragmentation evidence of urinary spiked peptides: 
Observed MSMS spectrum of pseudo-biomarker with m/z 1672.91.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-541-S4.pdf]
Additional file 5
MSMS spectra and fragmentation evidence of urinary spiked peptides: 
Mascot interpretation of MSMS fragmentation spectrum of pseudo-
biomarker with m/z 1672.91.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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PCA analysis of spiked and not-spiked healthy urine Figure 5
PCA analysis of spiked and not-spiked healthy urine. (a) Plot of the sample scores for PC1 and PC2 obtained from PCA 
analysis of the replicate analysis of a healthy volunteer's urine sample spiked (open triangle) or not (black circle) with calibrator 
peptides (Human angiotensin II (1046.54 Da 1X = 120 fmol/μl), neurotensin (1672.91 Da, 1X = 80 fmol/μl) and ACTH 18–39 
fragment (2465.19 Da, 1X = 100 fmol/μl)). (b) Plot of the loadings for PC1 and PC2 for spiked and non-spiked samples (spiked 
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